 NantHealth, Inc. NASDAQ: NH, a next-generation, evidence-based, personalized healthcare company, announced the publication of four abstracts on developmental therapeutics for immunotherapy, molecularly targeted agents and tumor biology during the American Society of Clinical Oncology ASCO 2020 Virtual Scientific Program. 